Montag, 21. Juni 2021
Navigation öffnen
Anzeige:
Keytruda Pantumor
Keytruda Pantumor
JOURNAL ONKOLOGIE – STUDIE
DURTRE-RAD

Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC

Rekrutierend

NCT-Nummer:
NCT03624231

Studienbeginn:
August 2018

Letztes Update:
12.09.2018

Wirkstoff:
Durvalumab, Tremelimumab

Indikation (Clinical Trials):
Carcinoma, Squamous Cell, Head and Neck Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Ulrich Keilholz

Collaborator:
Charite University, Berlin, Germany, AstraZeneca,

Studienleiter

Ulrich Keilholz, MD
Study Chair
Charité Comprehensive Cancer Center

Kontakt

Studienlocations
(1 von 1)

Interdisziplinäres Brustzentrum der Charité im Charité Comprehensive Cancer Center
Virchowweg 23
10117 Berlin
(Berlin)
DeutschlandRekrutierend» Google-Maps
Ansprechpartner:
Konrad Klinghammer, MD
Phone: +49 (0)30 450 564222
E-Mail: cccc-durtrerad@charite.de
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

The primary objective is to explore the feasibility and efficacy in terms of treatment discontinuation due to toxicity and in terms of 1-year progression free survival of a PDL1-Inhibitor plus a CTLA-4 Inhibitor in combination with radiotherapy and a PDL1-Inhibitor in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HNSCC in the poor prognostic subgroup.

Secondary objectives are to investigate the benefit of the addition of a CTLA-4 Inhibitor and/or a PDL1-Inhibitor to radiotherapy in terms of overall progression free survival, overall survival and to investigate the approach in terms of safety, chronic toxicity and quality of life.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Patients with locally advanced histopathologically confirmed HNSCC not candidate for primary surgical treatment

- No distant metastasis (M0)

- Tumor tissue available for central testing Patient with HPV/p16 negative disease (≤70% positively stained cells) as determined by central testing

- Adequate normal organ and marrow function

- Measurable tumor according to RECIST

- Patients must be expected to complete the treatment.

- Age > 18 years at time of study entry

- Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test upon study entry and be willing to use adequate contraceptive measurements as described in the protocol

- Non-sterilized males who are sexually active with a female partner of childbearing potential must be willing to use adequate contraceptive measurements as described in the protocol section 6.5.4

Exclusion Criteria:

- Participation in another clinical study with an investigational product during the last 3 months

- Prior or current anticancer treatment to the head and neck area (e.g. radical attempted or tumor reductive surgery, neo-adjuvant chemotherapy, EGFR inhibitors or radiotherapy).

- Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab

- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:

- Patients with vitiligo or alopecia

- Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement

- Any chronic skin condition that does not require systemic therapy

- Patients without active disease in the last 5 years may be included but only after consultation with the study physician

- Patients with celiac disease controlled by diet alone History of primary immunodeficiency

- History of allogeneic organ transplant

- History of another primary malignancy except for

- Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence

- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease

- Adequately treated carcinoma in situ without evidence of disease

- History of hypersensitivity to durvalumab and/or tremelimumab or any excipient

- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent

- Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

- Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results

- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control as described in the protocol from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period

- Distant metastasis

- Patients who are institutionalised by official order

- Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's Correction

- Receipt of live attenuated vaccination within 30 days prior to study entry step 2 or within 30 days of receiving durvalumab or tremelimumab

Studien-Rationale

Primary outcome:

1. Efficacy- 1-year progression free survival (PFS) (Time Frame - 1 year):
1-year progression free survival (PFS) depicted as the 1-year in-field-progression-free survival and 1-year distant metastasis free survival

2. Feasibility - Number of treatment discontinuations due to toxicity (Time Frame - During treatment):
number of treatment discontinuations due to toxicity

Secondary outcome:

1. Overall Survival (OS) (Time Frame - From date of randomization until the date of death, assessed up to 3 years):
defined as the time from patient inclusion to the date of death or date of last follow-up news

2. Safety - Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 (Time Frame - From date of randomization until the date of study assessed up to 3 years):
defined as event possibly related to study treatment and fulfills the criteria using CTCAE Version 4.03

3. Chronic toxicity -Number of participants with treatment-related adverse Events Lasting longer than 3 months as assessed by CTCAE v4.03 and/or RTOG/EORTC Late Radiation Morbidity Scoring Schema (Time Frame - From date of randomization until the date of study assessed up to 3 years):
defined as event lasting longer than 3 months and possibly related to study treatment and fulfills the criteria using CTCAE Version 4.03 and/or and/or RTOG/EORTC Late Radiation Morbidity Scoring Schema

4. Quality of life (QoL) - measured by EORTC QLQ-H&N35 and EORTC QLQ-C30) (Time Frame - From date of randomization until the date of study assessed up to 3 years):
defined as assessment for evaluation of medical and psychosocial interventions

Studien-Arme

  • Experimental: Arm 1
    Patients in arm 1 will receive a single dose of durvalumab of 1500 mg administered on day 1, 14 days prior to initiation of the radiotherapy. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. On week 5, 9, 13 and 17 patients will receive durvalumab (1500 mg) and tremelimumab (75 mg) for up to 4 doses/cycles and then continue 1500 mg durvalumab q4w starting on week 21 to complete a total of 12 months of therapy (overall 9 single doses durvalumab including the initial dose on day 1).
  • Experimental: Arm 2
    Patients in arm 2 will receive durvalumab (1500 mg) q4w starting on day 1. Radiotherapy with 35 fractions over 7 weeks (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks) will start on day 14. Overall patients will receive treatment with durvalumab mono up to a total of 12 months (up to 13 doses in total).

Geprüfte Regime

  • Durvalumab (MEDI4736):
    Durvalumab (1500 mg) starting on week 1 to complete a total of 12 months
  • Tremelimumab:
    Tremelimumab (75 mg) for up to 4 doses/cycles
  • Radiotherapy:
    Radiotherapy with 35 fractions (administered as daily fractions of 2 Gy given 5 days every week for 7 weeks)

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Junge Krebspatienten: Ausbildung und Familie, aber auch Angst und Schmerzen
Junge+Krebspatienten%3A+Ausbildung+und+Familie%2C+aber+auch+Angst+und+Schmerzen
© pathdoc / Fotolia.com

„Ich hatte große Träume für mein Leben, jetzt denke ich oft viel, viel kurzfristiger“, sagt die 25-jährige Studentin Mia*, die vor anderthalb Jahren an Krebs erkrankte. Nach der Diagnose musste sie ihr Studium unterbrechen, ihre Familienplanung in Frage stellen und auch mit ihrem Freundeskreis einen neuen Umgang finden. Sie ist eine von rund 15.000 jungen Menschen, die jährlich im Alter von 18 bis 39 Jahren...

Krebsblogger geben Einblick in ihre persönliche Krankheitsgeschichte
Krebsblogger+geben+Einblick+in+ihre+pers%C3%B6nliche+Krankheitsgeschichte
© TIMDAVIDCOLLECTION - stock.adobe.com

11 Krebsblogger folgten der Einladung des forschenden Pharmaunternehmens Janssen in die Deutschlandzentrale nach Neuss, um sich beim 3. gemeinsamen Workshop auszutauschen und ihre Geschichte zu erzählen. Sie sehen sich selbst als Kämpfer gegen Krebs und „Mut-Anker“ für andere. Janssen, die Pharmasparte des Gesundheitskonzerns Johnson & Johnson, unterstützt dieses Engagement. 2018 und 2019 fanden bereits ein...

Weltkrebstag: Deutsche Krebshilfe informiert und ruft zum Handeln auf
Weltkrebstag%3A+Deutsche+Krebshilfe+informiert+und+ruft+zum+Handeln+auf
© julief514 / Fotolia.com

Am 4. Februar ist Weltkrebstag. Das diesjährige Motto der Weltgesundheitsorganisation lautet: „Wir können. Ich kann.“ Es steht dafür, dass Menschen durch einen gesunden Lebensstil dazu beitragen können, vielen Krebsarten vorzubeugen. „Gesundheit ist ein hohes Gut und es macht Spaß etwas dafür zu tun“, betont Gerd Nettekoven, Vorstandsvorsitzender der Deutschen Krebshilfe. Die Organisation bietet Interessierten kostenlose Infomaterialien und...

EHA 2021
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose
  • PNH: Phase-III-Studie vergleicht Faktor-B-Inhibitor Iptacopan und monoklonale Anti-C5-Antikörper
  • Hochrisiko-MDS und AML: Sabatolimab + Decitabin/Azacitidin zeigt in Phase-I-Studie anhaltende Remissionen bei guter Verträglichkeit